ProPhase Labs, Inc. Current Assets
ProPhase Labs, Inc. (PRPH) had Current Assets of $2.80 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-19
- 2026-06-30: Assets, Current $2.80M.
- 2026-03-31: Assets, Current $2.85M; Assets, Current as first filed $3.11M.
- 2025-12-31: Assets, Current $3.15M.
- 2025-09-30: Assets, Current $7.77M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $2.85M 10-Q/A · filed 2026-07-09 | $3.11M 10-Q · filed 2026-06-30 |
| 2025-12-31 | $3.15M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $7.77M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $24.57M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $24.77M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $30.64M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $42.23M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $44.14M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $45.05M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $47.59M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $49.79M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $54.97M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $61.28M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $60.83M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $70.33M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $70.28M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $72.56M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $61.32M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $43.90M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $58.49M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $67.25M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $15.89M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $17.91M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $10.24M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $9.51M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $9.95M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $13.22M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $13.43M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $14.13M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $18.24M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $18.10M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $19.55M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $31.07M 10-Q/A · filed 2018-08-20 | $31.57M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $28.42M 10-K · filed 2019-03-26 | $28.92M 10-K · filed 2018-03-28 |
| 2017-09-30 | $33.73M 10-Q/A · filed 2018-08-20 | |
| 2017-06-30 | $42.22M 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | $49.66M 10-Q/A · filed 2018-08-20 | |
| 2016-12-31 | $9.63M 10-Q/A · filed 2018-08-20 | |
| 2016-09-30 | $9.73M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $8.48M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $10.27M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $11.88M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $10.84M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $9.18M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $12.44M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $13.46M 10-K · filed 2016-03-29 | |
| 2014-09-30 | $15.44M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $13.67M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $11.17M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $11.28M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $10.58M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $8.99M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $10.25M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $10.72M 10-K · filed 2014-03-27 | |
| 2012-09-30 | $10.51M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $9.18M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $12.05M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $13.20M 10-K · filed 2013-03-28 | |
| 2011-09-30 | $14.39M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $11.80M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $15.76M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |